Search Results - "CHAWLA, Sant P"

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy by DEMETRI, George D, CHAWLA, Sant P, REICHARDT, Peter, BOMPAS, Emmanuelle, ALCINDOR, Thierry, RUSHING, Daniel, YANG SONG, LEE, Ruey-Min, EBBINGHAUS, Scot, EID, Joseph E, LOEWY, John W, HALUSKA, Frank G, RAY-COQUARD, Isabelle, DODION, Pierre F, BLAY, Jean-Yves, LE CESNE, Axel, STADDON, Arthur P, MILHEM, Mohammed M, PENEL, Nicolas, RIEDEL, Richard F, BUI-NGUYEN, Binh, CRANMER, Lee D

“…Aberrant mammalian target of rapamycin (mTOR) signaling is common in sarcomas and other malignancies. Drug resistance and toxicities often limit benefits of…”
Get full text

Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model by Higuchi, Takashi, Miyake, Kentaro, Oshiro, Hiromichi, Sugisawa, Norihiko, Yamamoto, Norio, Hayashi, Katsuhiro, Kimura, Hiroaki, Miwa, Shinji, Igarashi, Kentaro, Chawla, Sant P., Bouvet, Michael, Singh, Shree Ram, Tsuchiya, Hiroyuki, Hoffman, Robert M.

“…Recurrent osteosarcoma is a chemotherapy-resistant disease. Individualized precision therapy is needed for this disease. Toward this goal, we have developed…”
Get full text

R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study by PAPPO, Alberto S, PATEL, Shreyaskumar R, GANJOO, Kristen N, SCHUETZE, Scott M, JUERGENS, Heribert, LEAHY, Michael G, GEOERGER, Birgit, BENJAMIN, Robert S, HELMAN, Lee J, BAKER, Laurence H, CROWLEY, John, REINKE, Denise K, KUENKELE, Klaus-Peter, CHAWLA, Sant P, TONER, Guy C, MAKI, Robert G, MEYERS, Paul A, CHUGH, Rashmi

“…The type 1 insulin-like growth factor 1 receptor (IGF-1R) has been implicated in the pathogenesis of the Ewing sarcoma family of tumors (ESFT). We conducted a…”
Get full text

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives by Gordon, Erlinda M., Sankhala, K. Kumar, Chawla, Neal, Chawla, Sant P.

“…Trabectedin (ET743, Yondelis ® , manufactured by Baxter Oncology GmbH, Halle/Westfalen, Germany, for Janssen Products, LP, Horsham, PA), derived from the…”
Get full text

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules by DEMETRI, George D, CHAWLA, Sant P, LEBEDINSKY, Claudia, ELSAYED, Yusri A, IZQUIERDO, Miguel A, GOMEZ, Javier, PARK, Youn C, LE CESNE, Axel, VON MEHREN, Margaret, RITCH, Paul, BAKER, Laurence H, BLAY, Jean Y, HANDE, Kenneth R, KEOHAN, Mary L, SAMUELS, Brian L, SCHUETZE, Scott

“…To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic…”
Get full text

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas by CHAWLA, Sant P, STADDON, Arthur P, RIVERA, Victor M, CLACKSON, Tim, LOEWY, John W, HALUSKA, Frank G, DEMETRI, George D, BAKER, Laurence H, SCHUETZE, Scott M, TOLCHER, Anthony W, D'AMATO, Gina Z, BLAY, Jean-Yves, MITA, Monica M, SANKHALA, Kamalesh K, BERK, Lori

“…Ridaforolimus is an inhibitor of mammalian target of rapamycin, an integral component of the phosphatidyl 3-kinase/AKT signaling pathway, with early evidence…”
Get full text

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311) by Chawla, Sant P, Tellez, Walter Andree, Chomoyan, Hripsime, Valencia, Chrysler, Ahari, Amir, Omelchenko, Nadezhda, Makrievski, Stefan, Brigham, Don A, Chua-Alcala, Victoria, Quon, Doris, Moradkhani, Ania, Gordon, Erlinda M

“…Intratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin…”
Get full text

Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model by Higuchi, Takashi, Sugisawa, Norihiko, Miyake, Kentaro, Oshiro, Hiromichi, Yamamoto, Norio, Hayashi, Katsuhiro, Kimura, Hiroaki, Miwa, Shinji, Igarashi, Kentaro, Chawla, Sant P, Bouvet, Michael, Singh, Shree Ram, Tsuchiya, Hiroyuki, Hoffman, Robert M

“…Recurrent osteosarcoma is a recalcitrant disease; therefore, an improved strategy is urgently needed to provide therapy. In order to develop a novel strategy…”
Get full text

A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers by Kenney, Richard T, Cini, John K, Dexter, Susan, DaFonseca, Manuel, Bingham, Justus, Kuan, Isabelle, Chawla, Sant P, Polasek, Thomas M, Lickliter, Jason, Ryan, Philip J

“…The benefits of recombinant interleukin-12 (rIL-12) as a multifunctional cytokine and potential immunotherapy for cancer have been sought for decades based on…”
Get full text

Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy by SUGISAWA, NORIHIKO, MIYAKE, KENTARO, HIGUCHI, TAKASHI, OSHIRO, HIROMICHI, ZHANG, ZHIYING, PARK, JUN HO, KAWAGUCHI, KEI, CHAWLA, SANT P., BOUVET, MICHAEL, SINGH, SHREE RAM, UNNO, MICHIAKI, HOFFMAN, ROBERT M.

“…Background/Aim: Gemcitabine is standard first-line treatment for patients with advanced pancreatic cancer, however the efficacy is limited. Although acquired…”
Get full text

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group by HESKETH, Paul J, GRUNBERG, Steven M, EVANS, Judith K, BECK, Klaus, REINES, Scott, HORGAN, Kevin J, GRALLA, Richard J, WARR, David G, ROILA, Fausto, DE WIT, Ronald, CHAWLA, Sant P, CARIDES, Alexandra D, LANUS, Juliana, ELMER, Mary E

“…In early clinical trials with patients receiving highly emetogenic chemotherapy, the neurokinin antagonist aprepitant significantly enhanced the efficacy of a…”
Get full text

Editorial: Celebrating the 200th mendel's anniversary: gene-targeted diagnostics and therapies for cancer by Federman, Noah, Gordon, Erlinda M, Chawla, Sant P, Hall, Frederick L

Get full text

A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results by Attia, Steven, Bolejack, Vanessa, Ganjoo, Kristen N., George, Suzanne, Agulnik, Mark, Rushing, Daniel, Loggers, Elizabeth T., Livingston, Michael B., Wright, Jennifer, Chawla, Sant P., Okuno, Scott H., Reinke, Denise K., Riedel, Richard F., Davis, Lara E., Ryan, Christopher W., Maki, Robert G.

“…Background Regorafenib is one of several FDA‐approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype‐specific data…”
Get full text

Giant-cell tumor of bone : treatment options and role of denosumab by Singh, Arun S, Chawla, Neal S, Chawla, Sant P

“…Discusses the role of denosumab, a monoclonal antibody against receptor activator of nuclear factor-κB ligand (RANKL), in modifying the pathogenesis of…”
Get full text

Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast by Bruckner, Howard W, Chawla, Sant P, Omelchenko, Nadezhda, Brigham, Don A, Gordon, Erlinda M

“…Metastatic breast cancer is associated with a poor prognosis and therefore, innovative therapies are urgently needed. Here, we report on the results of a Phase…”
Get full text

A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer by Chawla, Sant P., Bruckner, Howard, Morse, Michael A., Assudani, Nupur, Hall, Frederick L., Gordon, Erlinda M.

“…Rexin-G is a replication-incompetent retroviral vector displaying a cryptic SIG-binding peptide for targeting abnormal Signature (SIG) proteins in tumors and…”
Get full text

A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 by Somaiah, Neeta, Chawla, Sant P., Block, Matthew S., Morris, John C., Do, Khanh, Kim, Joseph W., Druta, Mihaela, Sankhala, Kamalesh K., Hwu, Patrick, Jones, Robin L., Gnjatic, Sacha, Kim-Schulze, Seunghee, Tuballes, Kevin, Yishak, Mahlet, Lu, Hailing, Yakovich, Adam, Ter Meulen, Jan, Chen, Michael, Kenney, Richard T., Bohac, Chet, Pollack, Seth M.

“…Preclinical data suggest that a "prime-boost" vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost,…”
Get full text

Qualitative study to characterize patient experience and relevance of patient-reported outcome measures for patients with metastatic synovial sarcoma by Eliason, Laurie, Grant, Laura, Francis, Anya, Cardellino, Anna, Culver, Ken, Chawla, Sant P., Arbuckle, Rob, Pokras, Shibani

“…Background The outlook for patients with metastatic synovial sarcoma (mSS) is poor. Better understanding of patient experience in this setting, beyond clinical…”
Get full text

The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model by Miyake, Kentaro, Higuchi, Takashi, Oshiro, Hiromichi, Zhang, Zhiying, Sugisawa, Norihiko, Park, Jun Ho, Razmjooei, Sahar, Katsuya, Yuki, Barangi, Maryam, Li, Yunfeng, Nelson, Scott D., Murakami, Takashi, Homma, Yuki, Hiroshima, Yukihiko, Matsuyama, Ryusei, Bouvet, Michael, Chawla, Sant P., Singh, Shree Ram, Endo, Itaru, Hoffman, Robert M.

“…•Liposarcoma (LS) is a chemotherapy-resistant disease.•Developed dedifferentiated liposarcoma (DDLS) patient-derived orthotopic xenograft (PDOX)…”
Get full text

The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model by Higuchi, Takashi, Kawaguchi, Kei, Miyake, Kentaro, Oshiro, Hiromichi, Zhang, Zhiying, Razmjooei, Sahar, Wangsiricharoen, Sintawat, Igarashi, Kentaro, Yamamoto, Norio, Hayashi, Katsuhiro, Kimura, Hiroaki, Miwa, Shinji, Nelson, Scott D., Dry, Sarah M., Li, Yunfeng, Chawla, Sant P., Eilber, Frederick C., Singh, Shree Ram, Tsuchiya, Hiroyuki, Hoffman, Robert M.

“…•Undifferentiated/unclassified soft-tissue sarcomas (USTS) is recalcitrant neoplasms.•Determine the efficacy of nab-PTX in combination with GEM.•Tumor growth…”
Get full text